Market Research Logo

Orion Oyj (ORNBV) - Financial and Strategic SWOT Analysis Review

Orion Oyj (ORNBV) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Orion Oyj (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Oyj Key Recent Developments

Jul 19,2017: Orion Group Half-Year Financial Report January-June 2017
Apr 26,2017: Orion Group Interim Report January–March 2017
Apr 11,2017: Pharmaceutical leader Orion selects Determine to optimize their global Source-to-Contract effectiveness
Feb 13,2017: Change in Orion Group Executive Management Board as of 21 February 2017
Feb 10,2017: Orion Research Foundation grants EUR 1 million for research

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 5
Orion Oyj - Key Facts 5
Orion Oyj - Key Employees 6
Orion Oyj - Key Employee Biographies 7
Orion Oyj - Major Products and Services 8
Orion Oyj - History 11
Orion Oyj - Company Statement 12
Orion Oyj - Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Section 2 – Company Analysis 16
Orion Oyj - Business Description 16
Orion Oyj - Corporate Strategy 18
Orion Oyj - SWOT Analysis 19
SWOT Analysis - Overview 19
Orion Oyj - Strengths 19
Orion Oyj - Weaknesses 20
Orion Oyj - Opportunities 21
Orion Oyj - Threats 22
Orion Oyj - Key Competitors 23
Section 3 – Company Financial Ratios 24
Financial Ratios - Capital Market Ratios 24
Financial Ratios - Annual Ratios 25
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 – Company’s Lifesciences Financial Deals and Alliances 31
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Orion Oyj, Recent Deals Summary 33
Section 5 – Company’s Recent Developments 34
Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017 34
Apr 26, 2017: Orion Group Interim Report January–March 2017 43
Apr 11, 2017: Pharmaceutical leader Orion selects Determine to optimize their global Source-to-Contract effectiveness 44
Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 45
Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research 46
Feb 08, 2017: Orion Group Financial Statement Release for 2016 47
Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 50
Oct 25, 2016: Orion Group Interim Report January-September 2016 51
Jul 19, 2016: Orion Group Half-Yearly Report January-June 2016 52
Jun 15, 2016: Orion upgrades full-year outlook for 2016 58
Section 6 – Appendix 59
Methodology 59
Ratio Definitions 59
About GlobalData 63
Contact Us 63
Disclaimer 63
List of Tables
Orion Oyj, Key Facts 5
Orion Oyj, Key Employees 6
Orion Oyj, Key Employee Biographies 7
Orion Oyj, Major Products and Services 8
Orion Oyj, History 11
Orion Oyj, Subsidiaries 14
Orion Oyj, Key Competitors 23
Orion Oyj, Ratios based on current share price 24
Orion Oyj, Annual Ratios 25
Orion Oyj, Annual Ratios (Cont...1) 26
Orion Oyj, Annual Ratios (Cont...2) 27
Orion Oyj, Interim Ratios 29
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32
Orion Oyj, Recent Deals Summary 33
Currency Codes 59
Capital Market Ratios 59
Equity Ratios 60
Profitability Ratios 60
Cost Ratios 61
Liquidity Ratios 61
Leverage Ratios 62
Efficiency Ratios 62
List of Figures
Orion Oyj, Performance Chart (2012 - 2016) 28
Orion Oyj, Ratio Charts 30
Orion Oyj, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31
Orion Oyj, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report